Dizziness

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
onsdag, maj 8, 2024

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

Public Advisory - Fake Viagra seized from Jug City store in Scarborough, ON

Retrieved on: 
fredag, april 26, 2024

Health Canada has seized counterfeit Viagra from a Jug City store in Scarborough, Ontario (96 Dearham Wood).

Key Points: 
  • Health Canada has seized counterfeit Viagra from a Jug City store in Scarborough, Ontario (96 Dearham Wood).
  • This is in addition to several other unauthorised sexual enhancement products seized from the same store.
  • For more information regarding Health Canada's approach to counterfeit health products, please consult Health Canada's Policy on Counterfeit Health Products .
  • Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM).

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Retrieved on: 
onsdag, april 10, 2024

HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.

Key Points: 
  • "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
  • "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
  • Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
  • Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.

Samuel Rodgers Health Center embracing safe seated mammography powered by Enable Me; U.S. trend toward seated exams benefits patients and technologists

Retrieved on: 
tisdag, april 23, 2024

With safe seated mammography trending in the U.S., the Samuel U. Rodgers Health Center (Sam Rodgers) reports its use of the Danish made VELA Mammography Chair has provided significant physical benefits for patients, health benefits for mammographers, and better breast imaging.

Key Points: 
  • With safe seated mammography trending in the U.S., the Samuel U. Rodgers Health Center (Sam Rodgers) reports its use of the Danish made VELA Mammography Chair has provided significant physical benefits for patients, health benefits for mammographers, and better breast imaging.
  • The health center purchased the VELA Mammography Chair from Enable Me , a VELA Medical Company based in Florida.
  • Although falls during standing mammography are rare, Mrs. Jeria commented that patients who are anxious, nervous, who cannot relax and tense up may be prone to falling.
  • Mrs. Jeria recommended that before their next mammogram, women that find traditional standing mammography intimidating or uncomfortable should ask a facility representative if they offer seated mammography.

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

Retrieved on: 
torsdag, april 11, 2024

SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial.

Key Points: 
  • SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial.
  • The TELE-ACS clinical trial, conducted at a large tertiary center in London, UK, from January 2022 to April 2023, involved 337 participants.
  • Moreover, the study was also published in the leading Journal of the American College of Cardiology (JACC).
  • These groundbreaking clinical results are an endorsement that propels us forward in our mission to redefine patient care, demonstrating the tangible benefits and efficiency of our telemedicine solutions on a global scale."

Heart-Valve-Surgery.Com and Medtronic Launch Novel "Aortic Stenosis Patient Activation Platform" to Empower Patients

Retrieved on: 
torsdag, april 25, 2024

LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com , a leading patient advocacy group for heart valve disease, with support from Medtronic , a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.

Key Points: 
  • LOS ANGELES, April 25, 2024 /PRNewswire/ -- Heart-Valve-Surgery.com , a leading patient advocacy group for heart valve disease, with support from Medtronic , a global leader in healthcare technology, today launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.
  • Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly.
  • Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
  • Because treatment continues to increase and evolve, the "Aortic Stenosis Patient Activation Platform", developed by Heart-Valve-Surgery.com with support from Medtronic and a world-renowned team of physicians, will increase awareness and education for aortic stenosis patients.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
fredag, april 12, 2024

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

Migraine sufferers in England may soon be able to access preventative drug – here’s how atogepant works

Retrieved on: 
tisdag, april 23, 2024

Atogepant (brand name: Aquipta) was recently recommended by the National Institute for Health and Care Excellence (Nice) to prevent episodic and chronic migraine attacks.

Key Points: 
  • Atogepant (brand name: Aquipta) was recently recommended by the National Institute for Health and Care Excellence (Nice) to prevent episodic and chronic migraine attacks.
  • The drug would be recommended to people who have at least four migraine days a month or where at least three previous preventative treatments have failed.
  • Migraine is a complex neurological condition that affects about 10 million people in the UK.
  • It’s characterised by recurrent, severe headaches that can be made worse by physical activity and are often debilitating.
  • However, it’s only suited to patients who suffer from episodic migraines – whereas atogepant can be used by people who have both chronic and episodic migraines.

Consistently effective


Three clinical trials have shown atogepant to be safe and effective for people with episodic or chronic migraines.

  • The Advance trial evaluated how safe and effective different doses of atogepant were compared with a placebo in preventing episodic migraine.
  • The 60mg once-daily tablet was found to be well tolerated and effective, leading to nearly seven fewer migraine days per month.
  • A third trial, the 302-LTS trial, followed participants who suffered from episodic migraine for over a year, finding that atogepant was consistently effective for reducing migraine attacks.
  • Atogenpant was consistently shown to be safe across all studies, including the one that lasted for a year.


Anna Andreou receives funding from the Medical Research Foundation and Brain Research UK. She also received research funding from eNeura, AbbVie and Pfizer. She is affiliated with the International Headache Society, being elected as a Trustee of the Board. She is Chair of the Headache special interest group of the British Pain Society.

Getting a good night’s rest is vital for neurodiverse children – pediatric sleep experts explain why

Retrieved on: 
fredag, april 19, 2024

If you’re a parent with kids at home, it often leaves you and your children on edge.

Key Points: 
  • If you’re a parent with kids at home, it often leaves you and your children on edge.
  • Children with neurodiverse conditions, such as autism and attention-deficit/hyperactivity disorder, or ADHD, are even more susceptible to the effects of poor sleep, given their emotional reactivity and impulsivity..
  • Struggles with sleep have been linked to increased aggression, irritability, inattention and hyperactivity in children with autism spectrum disorder.

The science behind sleep difficulties

  • There are multiple reasons why neurodiverse children don’t sleep well, including medical conditions, biological causes and behavioral and environmental factors.
  • Medical conditions, such as obstructive sleep apnea or epilepsy, can affect a child’s sleep.
  • Medications that are used to treat medical conditions, such as antidepressants for mood disorders or stimulants for ADHD, can further disrupt sleep.

Treating sleep problems


All of these factors can be addressed and treated. A thorough evaluation by the child’s health care provider may reveal a medical cause, or medication, that is interfering with sleep. Behavioral approaches can make a big difference in improving sleep. These might include:
Changes to daytime habits, including getting lots of morning light and physical activity.
Shifts in evening habits, such as removing all screens (TV, computers, phones, etc.) and establishing calming bedtime routines.
Modifications to how a parent interacts with their child for those families who would like a child to fall asleep and stay asleep independently.

  • It’s important to note that not all families want their children to sleep on their own.
  • Because there are so many factors that can cause disrupted sleep, addressing sleep problems cannot be a one-size-fits-all approach and should be done in partnership with parents.
  • Our team has developed a family-centered approach to address sleep problems in neurodiverse children.

The ups and downs of melatonin

  • While behavioral approaches are recommended as a first-line treatment, melatonin can be helpful in jump-starting a behavioral routine.
  • Overdoses can result from children eating a bunch of gummies, or parents not understanding how much melatonin is safe to give.
  • To help parents sift through all the resources and articles on melatonin on the internet and social media, one of us created a video and wrote several blogs on melatonin safety.
  • These include topics like whether children can become dependent on melatonin supplements over time, whether taking melatonin will delay puberty, whether children might experience side effects from taking melatonin and more.

Promoting healthier sleep


Here are some general tips for helping your child sleep better, regardless of whether they are neurodiverse:
Choose a consistent bedtime and wake time. This consistency will help children’s own natural melatonin kick in.
Make sure bedtime isn’t too early. For example, an 8 p.m. bedtime is too early for most 10-year-olds. Neurodiverse children may struggle to sleep and will become more anxious, which makes going to sleep even harder.
Help your child get natural sunlight in the morning. Morning sunlight sets our brain’s internal clock so that we can fall asleep more easily at bedtime.
Ensure your child is getting physical activity during the day.
Minimize naps longer than one hour, or after 4 p.m. for school-age children. Naps can interfere with going to sleep at night.
Avoid caffeine, including many types of soda, tea and chocolate.
Turn off all screens and smartphones at least 30 minutes before bedtime.
In the evening leading up to bedtime, turn down all lights in the house. Consider using red night lights, if possible. Set any devices to night mode in the evening to limit exposure to blue light.
Create wind-down time in place of screens. Have your child identify an activity they enjoy that is calming and soothing, such as reading a book, coloring or listening to music. If a bath is stimulating, move it to earlier in the evening, such as after dinner.
Help your child learn to fall asleep without needing you or their devices to be there with them. That way, they will settle down on their own at bedtime. And when they wake up throughout the night, since we all wake up in the night, they will be able to go right back to sleep without becoming fully awake.
For more tips, see Autism Speaks for free downloads of brochures and visual aids.

  • She also receives funding from the American Academy of Sleep Medicine.
  • She has received funding from the American Academy of Sleep Medicine and Autism Speaks for research on sleep in children with ASD.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
tisdag, mars 26, 2024

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.